TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04005326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quadratus lumborum block; (Anterior QLB or QLB III)
Description: The patient will be in the lateral position. A low frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suprainguinal fascia iliaca block
Description: In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subarachnoid block
Description: Patients will receive SAB using 25g spinal needle in the lateral position. Fifteen milligrams of hyperbaric bupivacaine will be administered at L3-L4 or at L4-L5 interspace in addition to 25 mcg fentanyl with rapid crystalloid co-load.~Spinal anesthesia will be considered successful when a bilateral block to T12, as assessed by loss of cold (cold ice) and pain (a 23-gauge needle) sensations, will be established 10 -minutes after the intrathecal injection. If spinal anesthesia failed, such patients will be administered general anesthesia and will be excluded from this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subarachnoid block
Description: Patients will receive SAB using 25g spinal needle in the lateral position. Fifteen milligrams of hyperbaric bupivacaine will be administered at L3-L4 or at L4-L5 interspace in addition to 25 mcg fentanyl with rapid crystalloid co-load.~Spinal anesthesia will be considered successful when a bilateral block to T12, as assessed by loss of cold (cold ice) and pain (a 23-gauge needle) sensations, will be established 10 -minutes after the intrathecal injection. If spinal anesthesia failed, such patients will be administered general anesthesia and will be excluded from this study.
Study: NCT00831883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner-Specific IMB-based HIV risk reduction intervention
Description: 5 session partner-specific HIV risk reduction group intervention based on the Information-Motivation-Behavioral Skills model.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Lifestyle
Description: 5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
Study: NCT00666042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigamox - administration in spray form
Description: Vigamox will be administered in a spray form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox eye drops
Description: Vigamox eye drops
Study: NCT06322901

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap
Description: Different flap designs for implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flap
Description: Different flap designs for implant placement
Study: NCT02071732

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real repetitive Transcranial Magnetic Stimulation
Study: NCT02071732

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive Transcranial Magnetic Stimulation
Description: This sham stimulation is not true stimulation.
Study: NCT04432207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-201 (administered as PD1-Vaxx) - Regimen 2
Description: IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every subsequent 63 days until discontinuation from study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-201 (administered as PD1-Vaxx) - Regimen 3
Description: IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every 56 or 63 days until discontinuation from study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-201 (administered as PD1-Vaxx) - Regimen 3
Description: IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every 56 or 63 days until discontinuation from study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-201 (administered as PD1-Vaxx) - Regimen 3
Description: IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every 56 or 63 days until discontinuation from study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-201 (administered as PD1-Vaxx) - Regimen 3
Description: IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every 56 or 63 days until discontinuation from study.
Study: NCT00437073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
Study: NCT04432207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.
Study: NCT00437073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: lapatinib administered 1250mg once daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: lapatinib administered 1250mg once daily orally
Study: NCT04652297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10356
Description: Single dose of HS-10356

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10356
Description: Multiple doses of HS-10356

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple doses of Placebo
Study: NCT04248153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR55
Description: BR55 will be administered at doses of 0.03 mL/kg or 0.05 mL/kg
Study: NCT03657446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h
Study: NCT03657446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h
Study: NCT01342042

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rExenatide-4
Description: This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster) (Eng et al, 1992). A mammalian homolog does not seem to exist (Pohl and Wank, 1998). Exendin-4 shares 53 % identity at the amino acid level with that of the mammalian hormone GLP-1 \[glucagon-like peptide-1\] (Chen and Drucker, 1997). Exendin-4 is encoded within a prohormone that is distinct from the prohormone encoding glucagon. Using transgenic mice expressing exendin-4, Adatia et al (2002) have shown that mammalian cells process the lizard prohormone in endocrine and nonendocrine cell types in vitro and in murine tissues in vivo.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rExenatide-4
Description: This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster) (Eng et al, 1992). A mammalian homolog does not seem to exist (Pohl and Wank, 1998). Exendin-4 shares 53 % identity at the amino acid level with that of the mammalian hormone GLP-1 \[glucagon-like peptide-1\] (Chen and Drucker, 1997). Exendin-4 is encoded within a prohormone that is distinct from the prohormone encoding glucagon. Using transgenic mice expressing exendin-4, Adatia et al (2002) have shown that mammalian cells process the lizard prohormone in endocrine and nonendocrine cell types in vitro and in murine tissues in vivo.
Study: NCT01013259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mutaflor
Description: 1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule matching the experimental treatment, according to the experimental arm
Study: NCT02163356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide/LXS Oral Powder
Description: Oral Powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Oral Tablet
Study: NCT03657446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet containing 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet containing 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet containing 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet containing 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet containing 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet containing 400 mg moxifloxacin
Study: NCT03397173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, allowing interruptions for weekends and holidays within each 28-day cycle. No dose modifications will be permitted during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle. No dose modifications will be permitted during the treatment period.
Study: NCT03090841

Intervention type: BIOLOGICAL
Intervention: Bio-specimen collected

Intervention type: BIOLOGICAL
Intervention: Bio-specimen collected
Study: NCT02098252

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurosurgery
Description: Surgical resection to be used when the lesion is considered by a multidisciplinary team to be safely 'operable'.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: when the AVM is smaller than 3 cm, and considered to not be safely 'operable'.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embolization
Description: Curative embolization, when the lesion is considered curable by embolization.
Study: NCT02163356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV
Study: NCT02725034

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard endoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High definition endoscopy with Optic Enhancement
Study: NCT02572388

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-M1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-M1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-M1
Study: NCT04833673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMR: Progressive Muscle Relaxation
Description: tensing and relaxing the body muscles accompanied with deep breathing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRT:Benson Relaxation Technique
Description: relaxation using mental imagery and mediation
Study: NCT00161473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prazosin
Description: Participants taking prazosin. Prazosin was administered as 1 or 2 mg capsules. Doses were initiated at 1 mg at bedtime. Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4mg at bedtime.~Duration was 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (inert substance)
Description: Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.
Study: NCT01368978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InsuPatch
Description: device which apply local heating at 38.5 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site.
Study: NCT04432207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care chemotherapy
Description: Chemotherapy to be administered according to the prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care chemotherapy
Description: Chemotherapy to be administered according to the prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care chemotherapy
Description: Chemotherapy to be administered according to the prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care chemotherapy
Description: Chemotherapy to be administered according to the prescribing information.
Study: NCT01186562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg PO daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00398073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mouse gp100 plasmid DNA vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mouse gp100 plasmid DNA vaccine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Dermal PowderMed® devices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intramuscularly (IM injection)
Study: NCT02304978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group CRC
Description: blood samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group control
Description: Blood samples
Study: NCT02520453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01006369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: hydroxychloroquine 200 mg po BID daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: hydroxychloroquine 200 mg po BID daily
Study: NCT00088699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study: NCT02231918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIRAPEX® - low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIRAPEX® - medium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIRAPEX® - high
Study: NCT01568515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electronic Message
Description: Students enrolled in the intervention group received 7 electronic contacts over a 7-month period. Specifically, participants received 4 electronic education messages, 2 electronic reminder/education messages, as well as 1 baseline and 1 final assessment contacts. Up to 4 reminder contacts were used if surveys were not completed for both intervention and control group participants. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment. Up to 4 reminder contacts were used if surveys were not completed. Intervention \& control groups were compared longitudinally for 7 months on the differences in HPV vaccine utilization and adherence, knowledge and attitudes about HPV, and the HPV vaccine (parallel design).
Study: NCT06246760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Incremental exercise test until volitional exhaustion
Study: NCT04450888

Intervention type: OTHER
Group type: OTHER
Intervention: The strategic use of messages in risk communication
Description: The interventions in the EMT-OCSP study are strategic health messages delivered (gain-framed vs.loss-framed and long-term vs.short-term contexts) to individuals based on their calculated CVD-free life expectancy and potential interventional benefits.
Study: NCT00088699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04450888

Intervention type: OTHER
Group type: OTHER
Intervention: The strategic use of messages in risk communication
Description: The interventions in the EMT-OCSP study are strategic health messages delivered (gain-framed vs.loss-framed and long-term vs.short-term contexts) to individuals based on their calculated CVD-free life expectancy and potential interventional benefits.

Intervention type: OTHER
Group type: OTHER
Intervention: The strategic use of messages in risk communication
Description: The interventions in the EMT-OCSP study are strategic health messages delivered (gain-framed vs.loss-framed and long-term vs.short-term contexts) to individuals based on their calculated CVD-free life expectancy and potential interventional benefits.
Study: NCT02120261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
Study: NCT04096235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAM Nasal Cannula
Description: The RAM Nasal Cannula is a means of providing CPAP and Bi-PAP to infants 28-42 weeks gestation to prevent nasal septal erosion.